Galapagos Nv Adr Stock Today
| GLPG Stock | USD 27.64 0.48 1.71% |
Performance0 of 100
| Odds Of DistressLess than 46
|
Galapagos is trading at 27.64 as of the 30th of November 2024. This is a 1.71% down since the beginning of the trading day. The stock's lowest day price was 27.62. Galapagos has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Galapagos NV ADR are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of May 2005 | Category Healthcare | Classification Health Care |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 65.9 M outstanding shares of which 1.5 M shares are currently shorted by private and institutional investors with about 5.94 trading days to cover. More on Galapagos NV ADR
Moving against Galapagos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Galapagos Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Name | Galapagos NV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, BEL-20 INDEX, AMX-Index, NASDAQ Biotechnology, BEL All Share, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGalapagos can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Galapagos' financial leverage. It provides some insight into what part of Galapagos' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Galapagos NV ADR (GLPG) is traded on NASDAQ Exchange in USA. It is located in Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 and employs 1,123 people. Galapagos is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.85 B. Galapagos NV ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.9 M outstanding shares of which 1.5 M shares are currently shorted by private and institutional investors with about 5.94 trading days to cover.
Galapagos NV ADR currently holds about 4.43 B in cash with (405.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 67.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Galapagos Probability Of Bankruptcy
Ownership Allocation30% of Galapagos NV ADR outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Galapagos Ownership Details
Galapagos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Stonepine Capital Management Llc | 2024-06-30 | 485 K | |
| Wellington Management Company Llp | 2024-06-30 | 345.1 K | |
| Millennium Management Llc | 2024-06-30 | 341.6 K | |
| Renaissance Technologies Corp | 2024-09-30 | 291.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 227.5 K | |
| Vestal Point Capital Lp | 2024-06-30 | 180 K | |
| Ecor1 Capital, Llc | 2024-09-30 | 155 K | |
| Dafna Capital Management Llc | 2024-09-30 | 130.2 K | |
| Norges Bank | 2024-06-30 | 120 K | |
| Fmr Inc | 2024-09-30 | 1.6 M | |
| Bvf Inc | 2024-09-30 | 1.6 M |
Galapagos Historical Income Statement
Galapagos Stock Against Markets
Galapagos Corporate Management
| Andre Hoekema | Sr. VP of Corporate Devel. | Profile | |
| John Montana | Managing Argenta | Profile | |
| Walid AbiSaab | Member of the Executive Committee, Chief Medical Officer | Profile | |
| Marieke Vermeersch | Head Communication | Profile | |
| Patrik Ringblom | Head Lead | Profile | |
| Ellen Aar | Head Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galapagos. If investors know Galapagos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galapagos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.748 | Earnings Share (0.96) | Revenue Per Share 0.1977 | Quarterly Revenue Growth (0.50) | Return On Assets (0.02) |
The market value of Galapagos NV ADR is measured differently than its book value, which is the value of Galapagos that is recorded on the company's balance sheet. Investors also form their own opinion of Galapagos' value that differs from its market value or its book value, called intrinsic value, which is Galapagos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galapagos' market value can be influenced by many factors that don't directly affect Galapagos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.